Kymera Therapeutics Analyst Ratings
BenzingaApr 22 07:27 ET
Kymera Therapeutics Analyst Ratings
BenzingaMar 1 08:33 ET
Kymera Therapeutics (KYMR) Receives a Buy From Truist Financial
TipRanksMar 1 07:35 ET
Kymera Therapeutics Analyst Ratings
BenzingaFeb 27 10:26 ET
Maintaining Hold on Kymera Therapeutics Amidst Promising Pipeline and Industry Challenges
TipRanksFeb 25 23:27 ET
Kymera Therapeutics Analyst Ratings
BenzingaFeb 23 08:56 ET
Stifel Nicolaus Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
TipRanksFeb 23 07:32 ET
Maintaining Hold on Kymera Therapeutics With a Cautious Outlook Amidst Pipeline Progression and Financial Stability
TipRanksFeb 23 06:01 ET
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Morphic Holding (MORF)
TipRanksFeb 22 15:20 ET
Kymera Therapeutics Analyst Ratings
BenzingaFeb 15 06:43 ET
Hold Rating on Kymera Therapeutics Amid Promising R&D but Early-Stage Valuation Uncertainties
TipRanksJan 9 00:55 ET
Morgan Stanley Raises Price Target on Kymera Therapeutics to $33 From $24, Keeps Equalweight Rating
MT NewswiresJan 8 07:53 ET
Hold Rating on Kymera Therapeutics Amid Early-Stage Program Developments and Pending Oncology Updates
TipRanksJan 8 05:06 ET
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Allogene Therapeutics (ALLO)
TipRanksJan 5 07:00 ET
B of A Securities Downgrades Kymera Therapeutics to Neutral, Lowers Price Target to $30
BenzingaJan 3 09:23 ET
Kymera Therapeutics Analyst Ratings
BenzingaJan 3 09:22 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: SCYNEXIS (SCYX) and Kymera Therapeutics (KYMR)
TipRanksJan 3 07:01 ET
Wells Fargo Downgrades Kymera Therapeutics to Equal-Weight, Announces $26 Price Target
BenzingaDec 19, 2023 09:23 ET
Kymera Therapeutics Analyst Ratings
BenzingaDec 19, 2023 09:21 ET
Hold Rating on Kymera Therapeutics Amidst Cautious Oncology Outlook and Long-Term Immunology Potential
TipRanksDec 19, 2023 06:26 ET
No Data
No Data